Outlook Therapeutics (OTLK) Equity Average: 2016-2020
Historic Equity Average for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to -$4.8 million.
- Outlook Therapeutics' Equity Average rose 72.41% to -$4.8 million in Q2 2020 from the same period last year, while for Jun 2020 it was -$4.8 million, marking a year-over-year increase of 72.41%. This contributed to the annual value of -$20.8 million for FY2019, which is 29.60% up from last year.
- Per Outlook Therapeutics' latest filing, its Equity Average stood at -$4.8 million for Q2 2020, which was up 81.42% from -$25.7 million recorded in Q1 2020.
- Outlook Therapeutics' Equity Average's 5-year high stood at -$1.8 million during Q3 2016, with a 5-year trough of -$31.3 million in Q3 2017.
- Moreover, its 3-year median value for Equity Average was -$23.5 million (2018), whereas its average is -$20.8 million.
- Per our database at Business Quant, Outlook Therapeutics' Equity Average plummeted by 1,633.97% in 2017 and then skyrocketed by 72.41% in 2020.
- Outlook Therapeutics' Equity Average (Quarterly) stood at -$13.5 million in 2016, then crashed by 117.51% to -$29.4 million in 2017, then grew by 11.64% to -$25.9 million in 2018, then rose by 9.32% to -$23.5 million in 2019, then skyrocketed by 72.41% to -$4.8 million in 2020.
- Its Equity Average stands at -$4.8 million for Q2 2020, versus -$25.7 million for Q1 2020 and -$23.5 million for Q4 2019.